Haemorrhagic cystitis (HC) is an important complication after bone marrow transplantation (BMT). Overt HC (grade у2, gross haematuria, clot retention and impairment of renal function), clinically more important than mild and occult HC (grade 1, microscopic haematuria), leads to substantial morbidity and occasional mortality. We retrospectively analyzed 32 cases of clinically overt HC from a series of 236 BMT patients. Significant risk factors included the use of busulphan during conditioning, allogeneic BMT and acute GVHD. Logistic regression showed GVHD to be the most important risk factor. According to the time of engraftment, HC could be divided into pre-and postengraftment subtypes. Pre-engraftment HC was brief, not more severe than grade 2, and subsided with supportive treatment. In contrast, post-engraftment HC was protracted, often of grade у3, associated with severe GVHD, and required surgical intervention in many cases. Polyoma BK viruria, but not adenoviruria, could be demonstrated in both types of HC. The increased severity and association with GVHD of postengraftment HC suggested that attack of urothelium by immunocompetent cells, possibly directed against BK viral antigens, might play a pathogenetic role.
commonly used in conditioning regimens. On the other hand, more severe HC causes gross haematuria that is often associated with clot retention and urinary tract obstruction. It is usually late in onset with a protracted course requiring persistent bladder irrigation and repeated cystoscopy and is a cause of severe morbidity and occasional mortality after BMT.
HC can be divided into four grades according to the severity of haematuria 4 (grade 1: microscopic haematuria; grade 2: macroscopic haematuria; grade 3: haematuria with clots; grade 4: macroscopic haematuria with clots and impaired renal function secondary to urinary tract obstruction). Clinically, HC can also be categorized into mild (sustained microscopic haematuria), moderate (gross haematuria and dysuria with or without clots) and severe (passage of clots with bladder pain requiring irrigation or presence of complications including urinary tract obstruction and renal function impairment requiring surgical intervention or chemical coagulation). 1 The risk factors associated with HC have been analysed in a number of studies. These included reactivation of the polyoma BK virus (BKV) and adenovirus (ADV) in the urothelium, older age at transplantation, allogeneic BMT and graft-versus-host disease. [8] [9] [10] [11] However, most of these risks have not been observed consistently.
Clinically overt HC (grade у2, clinically moderate to severe) causes the most morbidity and requires more specific treatment than occult HC with only microscopic haematuria. In this study, we analysed specifically the characteristics of clinically overt HC in a consecutive series of BMT patients, with a view to defining the risk factors associated with its occurrence.
Materials and methods

Patients
From January 1997 to December 2000, a total of 236 patients underwent BMT at Queen Mary Hospital, Hong Kong. Thirty-two patients developed clinically overt HC and were included in the analysis. None of these patients had a past history of documented urinary tract infection, bladder irradiation or radiological evidence of renal or bladder calculi.
Post-transplantation treatment
GVHD prophylaxis comprised methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6 and 11) and cyclosporin A (3 mg/kg intravenously or 8 mg/kg orally days 1-50, tailed off at 6 months). Patients receiving autologous BMT or allogeneic BMT from an HLA-identical sibling were given acyclovir (5 mg/kg every 8 h) for prophylaxis against herpes simplex infection, from the commencement of conditioning to day 30 post BMT. In patients undergoing allogeneic BMT from parents and MUD, high dose acyclovir (10 mg/kg every 8 h) was given from conditioning to marrow engraftment, followed by ganciclovir (5 mg/kg) three times a week until day 120, for prophylaxis against cytomegalovirus (CMV) infection. Pre-emptive ganciclovir therapy (5 mg/kg/day) was administered to patients with two consecutive PCR tests positive for CMV and continued until the PCR was negative on two occasions.
Prophylaxis against HC
Patients receiving cyclophosphamide-containing chemotherapy were given intravenous fluid at 3 l/m 2 /day from 4 h before to 24 h after the administration of cyclophosphamide. MESNA was given at a dose of 25 mg/kg prior to cyclophosphamide, and 75 mg/kg thereafter as a continuous infusion over 20 h until the last dose of cyclophosphamide.
Diagnosis and treatment of HC
At the time of HC, urine was sent for electron microscopy (EM) for the detection of viral particles, and polymerase chain reaction (PCR) for BKV and ADV as previously reported. 12 Briefly, DNA was extracted from the urinary sediment and amplified for the BKV VP1 gene (GeneBank accession number V01109, forward primer 5′-AGT GGA TGG GCA GCC TAT GTA-3′, reverse primer 5′-TCA TAT CTG GGT CCC CTG GA-3′), and the ADV hexon gene shared by serotypes 11, 34 and 35 (GeneBank accession number AB018424, forward primer 5′-ACT ACA TGA ACG GGC GGG T-3′, reverse primer 5′-GAG ACC ACC TGG CAC CAA TG-3′). The quantification of BKV in 20/32 patients included in this study has been reported elsewhere. 12 The treatment of HC included continuous bladder irrigation, flexible cystoscopy and evacuation of blood clots, intravesical alum or formalin instillation and electrical cauterization.
Statistical analysis
The probability of developing HC was calculated by the method of Kaplan and Meier. Comparison between groups of data was evaluated by the Mann-Whitney test and Fisher's exact test for numerical and categorical data. The effects of various parameters on the occurrence of HC were evaluated by binary logistic regression. P values of less than 0.05 were considered statistically significant.
Results
Clinical characteristics and risk of development of HC
The clinical features of patients with or without HC are shown in Table 1 . There was no significant difference in age and sex ratio between the two groups. However, the risk was significantly increased in patients who received busulphan-containing conditioning regimens (P = 0.008), underwent allogeneic BMT (P = 0.05), and developed GVHD (grade у2) (P = 0.02) (Figure 1 ). These risk factors were entered into a binary logistic regression analysis together with the age, gender and underlying diseases of the patients. Only the development of severe GVHD (grade у2) was significantly associated with HC (P Ͻ 0.001).
Clinicopathological features of HC
The clinical features of patients with clinically overt HC are shown in Tables 2 and 3 . If HC was separated into cases occurring before or after engraftment (absolute neutrophil count Ͼ0.5 × 10 9 /l), some interesting differences could be identified. HC after engraftment was more common, and often overt (grade у2) with a protracted course requiring bladder irrigation. On the other hand, HC before engraftment was less common, and often of lower grade (grade 2) which resolved spontaneously with supportive treatment. There was no significant difference between the two groups of patients in platelet counts at the onset of HC (P Ͼ 0.05).
BK viruria and AD viruria in HC
Twenty-five patients with HC had their urine examined by EM at the time of HC. BKV was found in 12 cases. PCR Table 1 Baseline clinical characteristics of patients for BKV was performed in 17 patients and all were positive, in cases both before and after engraftment. ADV was not detected in any case (Table 3) .
Clinical outcome
Continuous bladder irrigation and cystoscopy were performed in 14 patients. The median duration of bladder irrigation was 36 days (range: 5-90). Intravesicular formalin or alum instillation was undertaken in 10 patients. There was no HC-related mortality in this cohort of patients.
Discussion
The diagnosis of HC after BMT relies on the demonstration of haematuria. However, grade 1 HC manifesting as microscopic haematuria is indistinguishable clinically from other causes of haematuria such as thrombocytopenia, occult urinary tract infection and menstruation. Furthermore, microscopic haematuria/grade 1 HC is a mild condition of little clinical significance. On the other hand, HC of grade у2 is an important complication after BMT, leading to significant morbidity and occasional mortality. As most of the previous studies on HC have analysed all categories of HC irrespective of its severity 2, 4, 8, 9, 13 and timing of onset, 1,14 the risk factors leading to more severe grades of HC have not been well defined. In the present study, we have specifically studied the risk factors leading to clinically overt HC. We showed that it was associated with the use of busulphan, allogeneic BMT and the development of severe GVHD. Binary regression analysis showed that severe GVHD was the only significant risk factor.
We have further identified two patterns of HC based on their temporal relationships with marrow engraftment. The brief and relatively lower grade (grade 2) pre-engraftment HC contrasted with the prolonged and often serious (grades 3 and 4) post-engraftment HC. An interesting observation was that post-engraftment HC was also associated with more serious GVHD. With EM and PCR, we were able to show BKV in 2/5 patients with pre-engraftment HC, and 21/27 patients with post-engraftment HC. These results suggested that BKV might also be involved in the pathogenesis of both types of HC. 15 How can the various risk factors for HC be related to the types of HC? We propose a tentative model by which the effects of chemotherapy, allogeneic BMT/GVHD, and BKV might be used to explain the different clinical patterns of HC. During conditioning, chemotherapy induces urothelial damage and causes mild haematuria of short duration early in the course of transplantation. The prophylactic use of MESNA reduces the damage caused by cyclophosphamide, so that busulphan may become a risk factor. 15, 16 This notion has been further supported by different studies reported previously that showed the use of busulphan to be a significant risk factor for HC. 14, 17, 18 In addition, the immunosuppression during BMT results in reactivation of the dormant BKV in some cases. The increased replication of BKV, a cytopathic virus, also leads to urothelial damage and haematuria. 12 This sequence of events might explain HC of early onset. However, in late onset HC where the residual effects of chemotherapy would be much reduced, BKV and GVHD might be the more dominant factors. Infection of the urothelium with BKV leads to the expression of viral antigens that could conceivably be a target for reconstituted donor immuno-competent cells. 19, 20 This immune attack of the recipient urothelium by donor lymphoid cells might cause more damage, which might also last for longer, than simply the toxic effects of chemotherapy or the cytopathic effects of BKV, accounting for the observation that HC post engraftment is more serious and prolonged. 21 As this could be considered a special form of 'GVHD', it might therefore be expected that the concomitant presence of systemic GVHD could significantly contribute to the development of HC. Future studies should be conducted to determine whether the immunosuppression used for the treatment of systemic GVHD improves HC, and whether the duration of GVHD may also be related to the duration of HC.
Although this model is speculative, it generates hypotheses that can be tested. Modification of the conditioning regimen may reduce urothelial damage. More importantly, suppression of BKV replication may limit the immediate cytopathic effect, as well as the expression of viral antigens that lead to the putative delayed immune attack. Finally, immunosuppression might be considered as a treatment option which dampens immunological damage to the urothelium in post-engraftment HC. These propositions will need vigorously testing in prospective studies.
